Continuity Biosciences

Continuity Biosciences is an early-stage biotech innovator building a portfolio of precision drug delivery platforms designed to enhance the efficacy and safety of existing and emerging therapies. The company's core strategy involves creating implantable and localized systems—such as the NICHE platform for cell therapy and iontophoretic devices for targeted chemotherapy—that protect therapeutics and maximize impact at the disease site while minimizing systemic exposure. With a focus on significant unmet needs in Type 1 diabetes, pancreatic cancer, HIV, and other conditions, Continuity is positioning itself at the intersection of advanced engineering and deep biological insight. The company has secured strategic investment from Breakthrough T1D to advance its lead program toward human trials.

A suite of adaptive, precision delivery platforms including implantable cell encapsulation devices (NICHE), iontophoretic systems for localized drug delivery, nanofluidic implants for sustained release (NanoDDI), intratumoral drug-eluting seeds (NDES), and intradermal patch technology.

Continuity competes in the crowded and innovative field of drug delivery, facing competition from large medtech companies (e.g., Becton Dickinson, Medtronic), specialized drug delivery firms, and numerous biotech startups. Its differentiation lies in its specific engineering approaches (e.g., 3D-printed NICHE, nanofluidic implants) and its focus on creating protected microenvironments for both drugs and living cells.